





| Patient Information | Specimen Information | Client Information | |
|--|---|--------------------|--|
| DOB: AGE: | Specimen: TM225136E Requisition: 0000002 | Client #: | |
| Gender: F Fasting: N Phone: Patient ID: Health ID: | Collected: 09/18/2018 / 11:15 EDT Received: 09/19/2018 / 02:52 EDT Reported: 09/22/2018 / 10:21 EDT | | |

| COMMENTS: FASTING:NO | | · | | | |
|-------------------------|----------|--------------|-----------------|------------|------------|
| Test Name | In Range | Out Of Range | Reference Rang | ge Je | Lab |
| CBC (INCLUDES DIFF/PLT) | | | | | $	ext{TP}$ |
| WHITE BLOOD CELL COUNT | 5.6 | | 3.8-10.8 Thous | | |
| RED BLOOD CELL COUNT | 4.47 | | 3.80-5.10 Mill | | |
| HEMOGLOBIN | 13.1 | | 11.7-15.5 g/dI | Ļ | |
| HEMATOCRIT | 38.8 | | 35.0-45.0 % | | |
| MCV | 86.8 | | 80.0-100.0 fL | | |
| MCH | 29.3 | | 27.0-33.0 pg | | |
| MCHC | 33.8 | | 32.0-36.0 g/di | Ļ | |
| RDW | 12.8 | | 11.0-15.0 흥 | | |
| PLATELET COUNT | 236 | | 140-400 Thous | and/uL | |
| MPV | 10.4 | | 7.5-12.5 fL | | |
| ABSOLUTE NEUTROPHILS | 3237 | | 1500-7800 cell | ls/uL | |
| ABSOLUTE LYMPHOCYTES | 1842 | | 850-3900 cells | s/uL | |
| ABSOLUTE MONOCYTES | 493 | | 200-950 cells | /uL | |
| ABSOLUTE EOSINOPHILS | | 0 L | 15-500 cells/t | ūL | |
| ABSOLUTE BASOPHILS | 28 | | 0-200 cells/ul | Ĺ | |
| NEUTROPHILS | 57.8 | | 96 | | |
| LYMPHOCYTES | 32.9 | | واه ماه | | |
| MONOCYTES | 8.8 | | 8 | İ | |
| EOSINOPHILS | 0.0 | | o o | | |
| BASOPHILS | 0.5 | | ે | | |
| PROGESTERONE | 1.8 | | ng/mL | | $_{ m TP}$ |
| | | R | eference Ranges | : } | |
| | | Fema | ~ | | |
| | | F | ollicular Phase | < 1.0 | |
| | | L | uteal Phase | 2.6-21.5 | |
| | | | ost menopausal | < 0.5 | |
| | | | regnancy | | |
| | | | st Trimester | 4.1-34.0 | |
| | | _ | nd Trimester | 24.0-76.0 | |
| | | _ | | 52.0-302.0 | |
| ESTRADIOL | 150 | 9 | pg/mL | 52.0 502.0 | TP |
| 2011(1)2102 | 130 | Referen | ce Range | | |
| | | | cular Phase: | 19-144 | |
| | | Mid-C | | 64-357 | |
| | | | l Phase: | 56-214 | |
| | | | enopausal: | < or = 31 | |
| | | FOSCIII | enopausar: | < OT = 2T | |

Reference range established on post-pubertal patient population. No pre-pubertal reference range established using this assay. For any patients for whom low Estradiol levels are anticipated (e.g. males, pre-pubertal children and hypogonadal/post-menopausal females), the Quest Diagnostics Nichols Institute Estradiol, Ultrasensitive, LCMSMS assay is recommended (order code 30289).

Please note: patients being treated with the drug fulvestrant (Faslodex(R)) have demonstrated significant interference in immunoassay methods for estradiol measurement. The cross reactivity could lead to falsely elevated estradiol test results leading to an





AMD



| Patient Information | Specimen Information | Client Information |
|---------------------|--|--------------------|
| | Specimen: TM225136E Collected: 09/18/2018 / 11:15 EDT | |
| DOB: AGE: | Received: 09/19/2018 / 02:52 EDT | |
| Gender: F Fasting: | N Reported: 09/22/2018 / 10:21 EDT | 4 |
| Patient ID: | | |
| Health ID: | | |

Test Name In Range Out Of Range Reference Range Lab

inappropriate clinical assessment of estrogen status. Quest Diagnostics order code 30289-Estradiol, Ultrasensitive LC/MS/MS demonstrates negligible cross

reactivity with fulvestrant.

TESTOSTERONE, FREE

(DIALYSIS) AND TOTAL, MS

TESTOSTERONE, TOTAL, MS 114 H 2-45 ng/dL

For additional information, please refer to http://education.questdiagnostics.com/faq/TotalTestosteroneLCMSMSFAQ165 (This link is being provided for informational/educational purposes only.)

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

TESTOSTERONE, FREE

14.5 H

0.1-6.4 pg/mL

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

PERFORMING SITE:

AMD QUEST DIAGNOSTICS/NICHOLS CHANTILLY, 14225 NEWBROOK DRIVE, CHANTILLY, VA 20151-2228 Laboratory Director: PATRICK W. MASON,MD,PHD, CLIA: 49D0221801 TP QUEST DIAGNOSTICS-TAMPA, 4225 E. FOWLER AVE, TAMPA, FL 33617-2026 Laboratory Director: GLEN L HORTIN,MD,PHD, CLIA: 10D0291120